
Vitec (Q4 Preview) - Tough comparables in Q4, appealing valuation

Redeye revises its Base Case and estimates following an analyst change, retaining its positive view. While Q4 face tough comparable numbers, with Vitec trading at the lowest EV/Sales NTM since 2020, we believe the market is too pessimistic about the long-term prospects.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Vitec (Q4 Preview) - Tough comparables in Q4, appealing valuation